find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
60
Clinical Trials
Lymphoma
NA
Accepting Patients
nct/study# NA / PROCLIP
Prospective Multicenter International Observational Study For Determination Of A Cutaneous Lymphoma International Prognostic Index Model And Impact Of Major Therapies In Patients With Advanced Mycosis Fungoides And Sézary Syndrome Advanced Stage PROCLIPI Project By The Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance
Learn More
Lymphoma
NA
Accepting Patients
nct/study# NA / 2020-1089
Comparison Of Clinical Trials Enrollment In Patient Records And Claims
Learn More
Lymphoma
Phase II
Accepting Patients
nct/study# NCT04268706 / TESSCAR001
A Phase 2 Multi-Center Study Evaluating The Safety And Efficacy Of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) In Adult And Pediatric Patients With Relapsed Or Refractory CD30 Positive Classical Hodgkin Lymphoma (CHARIOT TESSCAR001)
Learn More
Lymphoma
Phase I
Accepting Patients
nct/study# NCT04277637 / BGB-11417-101
A Phase 1/1b Open-Label Dose Escalation And Expansion Study Of Bcl-2 Inhibitor BGB-11417 In Patients With Mature B-Cell Malignancies
Learn More
Lymphoma
Phase I/II
Accepting Patients
nct/study# NCT03420183 / ONCTERNAL-CIRM-0001
A Phase 1b-2 Study Of The ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), And The Bruton Tyrosine Kinase Inhibitor, Ibrutinib, In Patients With B-Cell Lymphoid Malignancies
Learn More
Lymphoma
Phase I/II
Accepting Patients
nct/study# NCT04224493 / EZH-302
A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.